Gast ::
| Hauptseite > Publikationsdatenbank > Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study > print |
| Hauptseite > Publikationsdatenbank > Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study > print |
| 001 | 824547 | ||
| 005 | 20210129225051.0 | ||
| 024 | 7 | _ | |a 10.3389/fneur.2015.00167 |2 doi |
| 024 | 7 | _ | |a 2128/13263 |2 Handle |
| 024 | 7 | _ | |a WOS:000363857200001 |2 WOS |
| 024 | 7 | _ | |a altmetric:4364819 |2 altmetric |
| 024 | 7 | _ | |a pmid:26284025 |2 pmid |
| 037 | _ | _ | |a FZJ-2016-07119 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Widman, Guido |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study |
| 260 | _ | _ | |a Lausanne |c 2015 |b Frontiers Research Foundation |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1482131515_5862 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Background: Antibodies (ABs) against the 65-kDa isoform of the intracellular enzymeglutamate decarboxylase (GAD65) have been found in limbic encephalitis (LE) andother neurological conditions. The direct significance of anti-GAD65-ABs for epilepsyis unclear. However, in histological preparations from biopsies of resective epilepsysurgeries, predominantly cytotoxic T-lymphocytes were detected making close contactsto neurons. Activated T-lymphocytes can, in turn, be selectively controlled by therapeuticinterleukin-2 receptor Abs, such as basiliximab.Case presentation: We report of a 25-year-old male patient with epilepsy since theage of 18 and displaying clinical signs of LE and a high titer of GAD65 ABs in cerebro-spinal fluid (CSF) and serum. Monthly, repetitive, intravenous cortisone pulse therapiesthat were initially administered for 6 months failed to improve his condition. Subsequentflow-cytometry analysis of CSF showed especially an increased fraction of activatedHLA-DR+CD8+T-lymphocytes (fCD8+TL) when compared to controls. Thus, a second,intravenous cortisone pulse therapy with an additional basiliximab dose of 20 mg/monthwas started. After 3 months, the fCD8+TL in the CSF normalized; after 6 months, thepsychological impulse-control deficits normalized; and after 11 months the patientwas seizure free. However, 7 weeks later, seizures and, later on, psychological deficitsrecurred and fCD8+TL was once again present in the CSF. Flumazenil PET, magneticresonance imaging-volumetry, and neuropsychological changes during therapy aredescribed.Conclusion: The correlation of the fCD8+TL in the CSF with clinical and paraclinical measures of disease activity combined with the unambiguous response to basiliximabstrongly argues in favor of the putative pathogenic role fCD8+TL in anti-GAD65 LE. The clinical relapse at the end of the observation period might be due to the formation ofhuman anti-drug ABs, a well-known complication of therapy with chimeric ABs. |
| 536 | _ | _ | |a 572 - (Dys-)function and Plasticity (POF3-572) |0 G:(DE-HGF)POF3-572 |c POF3-572 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Golombeck, Kristin |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Hautzel, Hubertus |0 P:(DE-Juel1)132313 |b 2 |u fzj |
| 700 | 1 | _ | |a Gross, Catharina C. |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Quesada, Carlos M. |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Witt, Juri-Alexander |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Rota Kops, Elena |0 P:(DE-Juel1)131788 |b 6 |u fzj |
| 700 | 1 | _ | |a Ermert, Johannes |0 P:(DE-Juel1)131818 |b 7 |u fzj |
| 700 | 1 | _ | |a Greschus, Susanne |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Surges, Rainer |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Helmstaedter, Christoph |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Wiendl, Heinz |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Melzer, Nico |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Elger, Christian E. |0 P:(DE-HGF)0 |b 13 |
| 773 | _ | _ | |a 10.3389/fneur.2015.00167 |g Vol. 6 |0 PERI:(DE-600)2564214-5 |p 167 |t Frontiers in neurology |v 6 |y 2015 |x 1664-2295 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/824547/files/Widman_Front_Neurol_2015.pdf |
| 856 | 4 | _ | |y OpenAccess |x icon |u https://juser.fz-juelich.de/record/824547/files/Widman_Front_Neurol_2015.gif?subformat=icon |
| 856 | 4 | _ | |y OpenAccess |x icon-1440 |u https://juser.fz-juelich.de/record/824547/files/Widman_Front_Neurol_2015.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |y OpenAccess |x icon-180 |u https://juser.fz-juelich.de/record/824547/files/Widman_Front_Neurol_2015.jpg?subformat=icon-180 |
| 856 | 4 | _ | |y OpenAccess |x icon-640 |u https://juser.fz-juelich.de/record/824547/files/Widman_Front_Neurol_2015.jpg?subformat=icon-640 |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/824547/files/Widman_Front_Neurol_2015.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:824547 |p openaire |p open_access |p driver |p VDB |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)132313 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131788 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)131818 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b FRONT NEUROL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)VDB145 |k KME |l Klinisch-Medizinische Einrichtungen (Univ. Düsseldorf) |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)VDB145 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | 1 | _ | |a FullTexts |
| 981 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 981 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|